A young male presented with second episode of depressive symptoms of one month duration; treatment started with fl uoxetine and on third week of starting of treatment, he developed sudden onset blurring of vision due to mydriasis which dramatically improved after discontinuation of fl uoxetine. There are evidences that selective serotonin reuptake inhibitors (SSRIs) can cause mydriasis through various mechanisms. Ocular side effects are rarely reported with SSRIs and we present such a case highlighting the same.
Introduction
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) with weak action on norepinephrine, M1 acetylcholine and weaker action on histamine 1, dopamine, and α1 and α2 receptors. It can cause blurring of vision due to mydriasis. Mydriasis is defi ned as dilatation of the pupil of the eye caused by contraction of the dilator muscle of the iris. [1] SSRIs can have some eff ect on the dilator muscle of eye and in clinical practice ocular side eff ects of SSRI are rarely encountered.
Case report
Mr Y, 30 years old male, 12 th pass, married, tailor by profession, belonging to lower socioeconomic strata came to psychiatry outpatient department (OPD) with the presenting complaints of pervasive low mood, decreased work interest, thoughts of worthlessness, occasional hopelessness, tearfulness, and decreased sleep for last one month. Th ere was no history of any precipitating or perpetuating factor, suicidal ideation, signifi cant anxiety symptoms, substance abuse, seizure disorder, or head injury.
He had similar episode two years back which had lasted for four months. He had received treatment with fl uoxetine in adequate doses along with benzodiazepine in tapering doses for a period of one year and patient did not report any signifi cant adverse eff ect to fl uoxetine and patient attained remission. Th ere was no history of psychiatric illness in his family. His premorbid functioning was well adjusted with no past history of medical and surgical illness. He was carrying out his job of tailor effi ciently.
In view of good response to fl uoxetine in the past episode, tab fl uoxetine 20 mg along with clonazepam 0.5 mg was started for two weeks. On follow up visit on the 16th day, the patient reported subjective improvement in his target symptoms of depression but with additional complaint of sudden onset blurring of vision and photophobia on the 16th day of starting treatment. As reported by the patient on the 16th day in the morning hours when the patient tried to put the thread in the needle of his sewing machine, he was not able to focus clearly in the eye of the needle and was unsuccessful aft er repeated attempts. Aft er that he tried to focus on minute embroidery works but could not visualise well. Patient rushed to the psychiatry OPD on the same day and reported this diffi culty. Patient was thoroughly assessed for emergence of this ocular symptom and no other causative factor could be associated except the treatment with fl uoxetine and clonazepam. Ophthalmology opinion was sought and near vision was found to be impaired. Fluoxetine was stopped immediately and asked the patient to review aft er fi ve days. On follow up visit, patient reported complete recovery of his symptoms aft er three days of stopping the medication. Patient was switched to venlafexine as its affi nity to serotonin and cholinergic receptor is weaker than fl uoxetine. Role of benzodiazepine in causing mydriasis is excluded as benzodiazepines are not known to cause this adverse eff ect in therapeutic doses.
Discussion

Possible mechanisms
Th e exact mechanism of SSRI induced mydriasis remains speculative, but relationship between serotonin and mydriasis has been proven by many studies and experiments. In patients with serotonin syndrome, mydriasis is also known ocular sign. [3] In patients, administration of fenfl uramine is associated with mydriasis, which induces release of serotonin. [4] Following are few hypothesis of SSRI induced mydrasis:
i. Mydriasis obviously can be explained via 5-HT1A receptor stimulation. [5] SSRI can cause mydriasis via 5HT1A receptor in ciliary muscle. ii. General central nervous system (CNS) stimulatory eff ect of serotonin may be responsible for mydriasis. [5] iii. Acute allergic reaction may be a possible mechanism, but in our case the onset was on 16 th day, so this mechanism was of remote possibility. [5] iv. Anticholinergic and adrenergic side eff ects of SSRI:
Drugs with anticholinergic and adrenergic activity are known to cause mydriasis. SSRIs have comparatively weak anticholinergic and adrenergic activity amongst which paroxetine has the highest potential for these adverse eff ects. [6] Th is case report pays focus on a rare adverse eff ect of fl uoxetine-blurring of vision due to mydriasis. Review of available literature shows SSRI induced certain ocular side eff ects, but does not defi ne any risk factor of patient likely to develop such adverse eff ects. Implication of presenting this case is to create awareness amongst doctors prescribing SSRI to counsel patient and to be vigilant regarding possibility of development of ocular side eff ect as this can be very troublesome to patient.
